-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Long Island Capital Alliance to Host Technology Capital Forum
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Who Is the Best MTF Top Surgeon?
-
APPA Launches 2026 Pet Industry Holiday Gift Guide, Backed by New Pet Gifting Data
-
United Bancorp, Inc. Increases its Fourth Quarter Cash Dividend Payment to $0.20 per Share, which Produces a Forward Yield of 5.4%
-
moveBuddha Doubles Moving Company Database to More Than 9,000 U.S. Movers
-
Montlick Injury Attorneys Brings Literacy and Lifesaving Booster Seat Safety Lessons to Atlanta Students
-
Mesothelioma Hope Remembers "Captain Dale" Perkins, Whose Story Reflects the Power of Connection and Support
-
Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money
-
BHG Financial Celebrates 25 Years of Innovation with Women in Technology Panel and Donates to Girls Who Code
-
Two Couples Will Win Valentine's Day Weddings at Love in Times Square Presented by David's Bridal
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare® topical and transdermal cannabis developments in the obesity market. The agreement will enhance the strategic partnership for innovative cannabinoid delivery technology with new developments and patent protection. MARKET Opportunity: The Global obesity therapy market by 2035 could reach US $150 billion U.S. dollars) (Morgan Stanley 2025).
Ovation and Skinvisible are building upon their original licensing and assignment agreement established on September 29, 2017. This enhanced collaboration centers on Skinvisible's proprietary Invisicare® technology for advanced polymer delivery systems targeting cannabinoid-based therapeutic products.
Exclusive Global Licensing Rights
Under the agreement, Ovation Science maintains exclusive worldwide rights to manufacture, private label, distribute, market, and promote licensed products utilizing Skinvisible's breakthrough delivery technology exclusively with cannabinoids. The agreement encompasses comprehensive access to confidential information; including proprietary formulations, processes, methodologies, specifications and trade secrets. Included is the recently filed PCT patent- pending application entitled: "Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent."
THC-V: A Promising Development for Metabolic Health
The expanded partnership specifically includes Skinvisible's latest innovation incorporating the cannabinoid THC-V (tetrahydrocannabivarin). Recent in-house research has demonstrated THC-V's potential as a therapeutic agent for obesity management, showing promising results as an appetite suppressant while improving metabolic function through enhanced insulin sensitivity and glucose control. Notably, THC-V offers these benefits without the psychoactive effects typically associated with THC. https://pubmed.ncbi.nlm.nih.gov/33526143/.
Addressing Critical Treatment Challenges
Skinvisible's Invisicare® technology represents a significant advancement in transdermal delivery systems for glucose-controlling agents. This innovative approach directly addresses one of the most persistent challenges in current obesity treatments: reducing gastrointestinal side effects that often limit patient compliance and treatment effectiveness.
The transdermal delivery method offers several advantages over traditional oral and injected medications, including improved bioavailability, reduced systemic side effects, and enhanced patient comfort and adherence to treatment protocols.
"We are excited to extend our cannabinoid development into the obesity / metabolic space," said Terry Howlett, Ovation's President. "Skinvisible has demonstrated that they can offer excellent science-based transdermal solutions. With these new developments and patent pending exclusivity we anticipate a positive impact to our financial results and creating value for our shareholders."
Market Opportunity
The global obesity therapy market presents substantial growth potential, with industry analysts projecting significant expansion through 2030. This partnership positions both companies to capitalize on the increasing demand for innovative, patient-friendly therapeutic solutions in the rapidly growing metabolic health sector.
Strategic Impact
These new developments leverage the strengths of both organizations: Skinvisible's cutting-edge delivery technology expertise and Ovation Science's cannabinoid background. Together, the companies are well-positioned to advance the development and distribution of next-generation cannabinoid-based therapeutics for metabolic disorders.
The collaboration underscores both companies' commitment to developing innovative solutions that improve patient outcomes while addressing unmet medical needs in the obesity and metabolic health markets.
About Ovation Science Inc.
Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; ARLO CBD Beauty and InVibe® MD ("wellness" line); all powered by its in-licensed patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a unique pipeline of proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Stock symbols: CSE:OVAT and OTC:OVATF
Websites: CORPORATE: www.ovationscience.com
WELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.com
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state or country cited, continued sales in dispensaries or in retail markets or expansion to other states or countries. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
CORPORATE and LICENSING INQUIRIES:
Doreen McMorran: [email protected] PH: 604-982-5700
SOURCE: Ovation Science Inc.
View the original press release on ACCESS Newswire
W.Moreno--AT